Astrocytoma: A Hormone-Sensitive Tumor?

Hirtz, Alex; Rech, Fabien; Dubois-Pot-Schneider, Hélène; Dumond, Hélène

doi:10.3390/ijms21239114

Cited by 45 publications

(44 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A debated topic without a definitive answer today is the role of hormones [26][27][28][29][30]. Interestingly, we did note a small but significant difference related to age at diagnostic surgery, with female patients generally being older, which could suggest a role for hormonal factors.…”

Section: Discussionmentioning

confidence: 60%

“…Estrogen is found at higher concentrations in female brains, where it binds to nuclear or membrane receptors. This leads to many different and complex effects that could contribute to the sex disparity [26]. While some studies have found a correlation of glioma incidence to exogenous hormone treatment, such as oral contraceptives or hormone replacement therapy, others have not [28,30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018

Tavelin

Malmström

2022

JCM

View full text Add to dashboard Cite

Sex disparities in glioblastoma (GBM) have received increasing attention. Sex-related differences for several molecular markers have been reported, which could impact on clinical factors and outcomes. We therefore analyzed data on all patients with GBM reported to the Swedish National Quality Registry for Primary Brain Tumors, according to sex, with a focus on prognostic factors and survival. All glioma patients registered during 20 years, from 1 January 1999 until 31 December 2018, with SNOMED codes 94403, 94413, and 94423, were analyzed. Chi2-test, log-rank test, and Kaplan–Meier analyses were performed. We identified 5243 patients, of which 2083 were females and 3160 males, resulting in a ratio of 1:1.5. We found sex related differences, with women having diagnostic surgery at a significantly higher age (p = 0.001). Women were also reported to have a worse preoperative performance status (PPS) (<0.001). There was no gender difference for the type of surgery performed. For women with radical surgery, overall survival was slightly better than for men (p = 0.045). The time period did not influence survival, neither for 1999–2005 nor 2006–2018, after temozolomide treatment was introduced (p = 0.35 and 0.10, respectively). In the multivariate analysis including sex, age, surgery, and PPS, a survival advantage was noted for women, but this was not clinically relevant (HR = 0.92, p = 0.006). For patients with GBM; sex-related differences in clinical factors could be identified in a population-based cohort. In this dataset, for survival, the only advantage noted was for women who had undergone radical surgery, although this was clinically almost negligible.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018

Tavelin

Malmström

2022

JCM

View full text Add to dashboard Cite

show abstract

“…Although little is known about GBM etiology, numerous sources indicate that women are 50% less likely to develop a GBM than men and respond better to standard treatment [ 7 , 8 ]. Thus, the circulating estrogens produced by the gonads or those synthetized locally in the brain could play a protective role against gliomagenesis [ 9 ]. This hypothesis is supported by observations linking exogenous hormone intake to a statistical increase in survival [ 7 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation

Hirtz

Lebourdais

Rech

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common brain tumor in adults, which is very aggressive, with a very poor prognosis that affects men twice as much as women, suggesting that female hormones (estrogen) play a protective role. With an in silico approach, we highlighted that the expression of the membrane G-protein-coupled estrogen receptor (GPER) had an impact on GBM female patient survival. In this context, we explored for the first time the role of the GPER agonist G-1 on GBM cell proliferation. Our results suggested that G-1 exposure had a cytostatic effect, leading to reversible G2/M arrest, due to tubulin polymerization blockade during mitosis. However, the observed effect was independent of GPER. Interestingly, G-1 potentiated the efficacy of temozolomide, the current standard chemotherapy treatment, since the combination of both treatments led to prolonged mitotic arrest, even in a temozolomide less-sensitive cell line. In conclusion, our results suggested that G-1, in combination with standard chemotherapy, might be a promising way to limit the progression and aggressiveness of GBM.

show abstract

“…Astrocytomas (AcTs), the most common gliomas, are tumors that originate in astrocytes, a type of glial cells star-shaped and localized in the cerebrum [ 172 ]. In adult individuals, AcTs are additionally the most common brain tumors, the most aggressive primary brain tumors, and those with the poorest vital prognosis [ 173 ].…”

Section: Primary Brain Tumorsmentioning

confidence: 99%

Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry

Sârbu

Ica

Zamfir

2022

IJMS

View full text Add to dashboard Cite

Gangliosides are effective biochemical markers of brain pathologies, being also in the focus of research as potential therapeutic targets. Accurate brain ganglioside mapping is an essential requirement for correlating the specificity of their composition with a certain pathological state and establishing a well-defined set of biomarkers. Among all bioanalytical methods conceived for this purpose, mass spectrometry (MS) has developed into one of the most valuable, due to the wealth and consistency of structural information provided. In this context, the present article reviews the achievements of MS in discovery and structural analysis of gangliosides associated with severe brain pathologies. The first part is dedicated to the contributions of MS in the assessment of ganglioside composition and role in the specific neurodegenerative disorders: Alzheimer’s and Parkinson’s diseases. A large subsequent section is devoted to cephalic disorders (CD), with an emphasis on the MS of gangliosides in anencephaly, the most common and severe disease in the CD spectrum. The last part is focused on the major accomplishments of MS-based methods in the discovery of ganglioside species, which are associated with primary and secondary brain tumors and may either facilitate an early diagnosis or represent target molecules for immunotherapy oriented against brain cancers.

show abstract

Astrocytoma: A Hormone-Sensitive Tumor?

Cited by 45 publications

References 137 publications

Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018

Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018

GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation

Gangliosides as Biomarkers of Human Brain Diseases: Trends in Discovery and Characterization by High-Performance Mass Spectrometry

Contact Info

Product

Resources

About